1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

$Thumbnail for Durability of Response, Mechanisms of Resistance, and Retreatment Outcomes Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review$

MM - 453

Durability of Response, Mechanisms of Resistance, and Retreatment Outcomes Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review

Mahboob Younus Shaik

Poster Presenter: Mahboob Younus Shaik

$Thumbnail for Durable Clinical Benefit of B-Cell Maturation Antigen (BCMA)-Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-8 Long-Term Responder (LTR) Analysis$

MM - 134

Durable Clinical Benefit of B-Cell Maturation Antigen (BCMA)-Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-8 Long-Term Responder (LTR) Analysis

Meletios A Dimopoulos

Poster Presenter: Meletios A Dimopoulos

MDS - 515

Durable Complete Remission Following HMA Therapy in Higher-Risk MDS Is Not Fully Determined by Baseline Disease Biology

Julie Braish

Poster Presenter: Julie Braish

Thumbnail for Duration of Minimal Residual Disease Negativity Predicts Durable Disease Control in Multiple Myeloma: A Meta-Analysis of 8900 Patients

MM - 072

Duration of Minimal Residual Disease Negativity Predicts Durable Disease Control in Multiple Myeloma: A Meta-Analysis of 8900 Patients

Rithika Manjunatha Reddy

Poster Presenter: Rithika Manjunatha Reddy

MM - 970

Early Acute Kidney Injury and Mortality in Critically Ill Patients With Multiple Myeloma: A Two-Cohort Study

Aroog Khaliq

Poster Presenter: Aroog Khaliq

Thumbnail for Early CD26? Leukemic Stem Cell Kinetics Can Predict Suboptimal Molecular Response and Switching TKIs during Chronic-Phase CML Therapy

CML - 1221

Early CD26? Leukemic Stem Cell Kinetics Can Predict Suboptimal Molecular Response and Switching TKIs during Chronic-Phase CML Therapy

Rudra Narayan Swain

Poster Presenter: Rudra Narayan Swain

Thumbnail for Early Cytarabine Escalation Does Not Improve Short-Term Outcomes Compared With Hydroxyurea-Only Cytoreduction in Hyperleukocytic Acute Myeloid Leukemia: A Real-World Propensity-Matched Analysis

AML - 1478

Early Cytarabine Escalation Does Not Improve Short-Term Outcomes Compared With Hydroxyurea-Only Cytoreduction in Hyperleukocytic Acute Myeloid Leukemia: A Real-World Propensity-Matched Analysis

Akshay Aluri

Poster Presenter: Akshay Aluri

$Thumbnail for Early Experience With Glofitamab (Glofit) Plus Polatuzumab Vedotin (Pola) As Bridging Therapy (BT) Prior to CD19-Directed CAR T-Cell Therapy in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)$

ABCL - 570

Early Experience With Glofitamab (Glofit) Plus Polatuzumab Vedotin (Pola) As Bridging Therapy (BT) Prior to CD19-Directed CAR T-Cell Therapy in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Yash Shah

Poster Presenter: Yash Shah

Thumbnail for Early Intervention vs Observation in High-Risk Smoldering Multiple Myeloma: Pooled Evidence From Randomized Trials and Real-World Cohorts

MM - 1189

Early Intervention vs Observation in High-Risk Smoldering Multiple Myeloma: Pooled Evidence From Randomized Trials and Real-World Cohorts

Sukhmani Sidhu

Poster Presenter: Sukhmani Sidhu